期刊
PEDIATRIC BLOOD & CANCER
卷 65, 期 3, 页码 -出版社
WILEY
DOI: 10.1002/pbc.26893
关键词
BRAF V600E inhibitor; child; desmoplastic infantile astrocytoma; infant; low-grade glioma; vemurafenib
资金
- German Childhood Cancer Foundation (Deutsche Kinderkrebsstiftung)
- Parents Initiative DLFH-Pfalz e.V.
Infants with low-grade glioma (LGG) and diencephalic syndrome have a poor outcome. The patient described here had a desmoplastic infantile astrocytoma harboring a BRAF V600E mutation. After relapse following initial standard chemotherapy treatment, he was successfully treated with the BRAF V600E inhibitor vemurafenib at the age of 3 years 11 months and 5 years 0 months. A rapid response was observed on both occasions. This illustrates the possibility of continuous oncogenic addiction and the therapeutic potential of BRAF V600E inhibitor monotherapy in LGG, even in very young severely compromised children. BRAF V600E inhibition in LGG and possible (re-)treatment regimens are briefly discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据